Zydus Lifesciences Limited (NSE: ZYDUSLIFE)
India
· Delayed Price · Currency is INR 962.70
-13.10 (-1.34%)
Feb 3, 2025, 3:30 PM IST
Zydus Lifesciences Revenue
Zydus Lifesciences had revenue of 52.37B INR in the quarter ending September 30, 2024, with 19.87% growth. This brings the company's revenue in the last twelve months to 214.84B, up 14.42% year-over-year. In the fiscal year ending March 31, 2024, Zydus Lifesciences had annual revenue of 195.47B with 13.40% growth.
Revenue (ttm)
214.84B
Revenue Growth
+14.42%
P/S Ratio
4.57
Revenue / Employee
7.98M
Employees
26,921
Market Cap
980.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 195.47B | 23.10B | 13.40% |
| Mar 31, 2023 | 172.37B | 21.28B | 14.08% |
| Mar 31, 2022 | 151.10B | 7.06B | 4.90% |
| Mar 31, 2021 | 144.04B | 1.50B | 1.06% |
| Mar 31, 2020 | 142.53B | 10.88B | 8.26% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 86.14B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 204.69B |
| Aurobindo Pharma | 302.95B |
| Alkem Laboratories | 128.32B |
| Fortis Healthcare | 73.13B |
Zydus Lifesciences News
- 9 days ago - Zydus Lifesciences chairman Pankaj R. Patel awarded Padma Bhushan for contributions to lifesciences - Business Upturn
- 22 days ago - Pharma Stocks Today: Biocon surges 4.41%, Mankind Pharma up 1.85%; Glaxo and Abbott India decline - Business Upturn
- 4 weeks ago - Zydus announces agreement with CVS Caremark to add Zituvio and combination products to its template formulary - Seeking Alpha
- 4 weeks ago - Zydus signs strategic agreement with CVS Caremark to add Zituvio , Zituvimet and ZituvimetTM to its template formulary - Business Upturn
- 4 weeks ago - Zydus Lifesciences announces U.S. FDA priority review for CUTX-101, a potential first-in-class treatment for Menkes disease - Business Upturn
- 5 weeks ago - Aurobindo Pharma (+1.58%), Mankind Pharma (+1.48%), Zydus Lifesciences (+0.91%) lead pharma stock gains - Business Upturn
- 5 weeks ago - Healthcare Sector Stock Update: Sun Pharma up 1.05%, Cipla up 1.22%, Zydus Lifesciences up 2% - Business Upturn
- 6 weeks ago - Zydus Lifesciences receives USFDA approval for Lidocaine and Prilocaine Cream USP - Business Upturn